2018 IPPF Pre-IID Meeting, Pemphigus and Pemphigoid:
“A New Era of Translational and Clinical Science”

May 15-16, 2018, Orlando, FL


Symposium Overview

The goal of the meeting is to bring together pemphigus and pemphigoid patients, clinicians, researchers, and industry partners to focus on ongoing or future clinical trials and their underlying science. In addition to clinical and scientific data, the agenda includes discussion of disease-specific instruments for use in clinical trials and a panel discussion with patients, investigators and industry describing their experience enrolling in clinical trials.


Symposium Venue: Rosen Shingle Creek Resort

9939 Universal Boulevard
Orlando, FL  32819

From Visit Florida: Orlando is a magical place. And it’s not just because it’s home to Cinderella’s castle at Walt Disney World. There’s an incredible mix of fun things to do in this great city that make it an ideal vacation spot for not only families but young singles, baby boomers, foodies, outdoor adventurous types, luxury shoppers and international visitors.

While the city was built on theme park fame, the number and variety of Orlando attractions have grown to include everything from world-famous restaurants to high-end outlet shopping centers to theatrical performances and amazing concert and sporting event venues.

Book now through the IID website.


Tuesday May 15, 2018

  • 11:00am – 12:00pm – Registration
  • 11:30am – 1:00pm – Lunch
  • 1:00pm – 1:15pm – Welcome and Conference Overview – Marc Yale, IPPF Executive Director

Session 1: What’s new in P/P clinical trials? 

This session covers ongoing or recently completed clinical trials in pemphigus and pemphigoid (P/P) registered on clinicaltrials.gov. 

1a. Pemphigus:
Moderators – John Stanley (Philadelphia, USA), Ron Feldman (Atlanta, USA)

  • 1:15pm – 1:30pmThe future of anti-CD20 B cell depletion in pemphigusPhilippe Musette, MD, PhD, RouenUniversity Hospital, Rouen, France
  • 1:30pm – 1:45pmBtk inhibition in pemphigus – Dedee Murrell, MD, University of New South Wales, Sydney, Australia
  • 1:45pm – 2:00pmFcRn inhibition in pemphigusRussell Hall, MD, Duke University, Durham, USA
  • 2:00pm – 2:15pmPanel discussion of clinical trials in pemphigus

1b. Pemphigoid:
Moderators – David Woodley (Los Angeles, USA), Enno Schmidt (Lübeck, Germany)

  • 2:30pm – 2:45pmPragmatic and non-inferiority studies in bullous pemphigoid – Karen Harman, MD, University Hospitals Leicester, Leicester, UK and University of Nottingham. Nottingham, UK
  • 2:45pm – 3:00pm – A pilot phase 2a study of the safety and efficacy of Bertilimumab, an anti-eotaxin-1 antibody in bullous pemphigoid – Neil Korman, MD, Case Western Reserve University, Cleveland, USA
  • 3:00pm – 3:15pmRecent clinical trials in pemphigoid – Janet Fairley, MD, University of Iowa, Iowa City, USA
  • 3:15pm – 3:30pm – Panel discussion of clinical trials in bullous pemphigoid
  • 3:30pm – 3:45pm – Coffee Break

Session 2: Clinical trial enrollment and outcomes 

Moderators – Katerina Patsatsi (Thessaloniki, Greece), Michael Hertl (Marburg, Germany)
This session will discuss and compare data using disease-specific instruments that may help to determine clinical trials enrollment and outcomes.

  • 3:45pm – 4:00pm – Quantifying disease extent throughout the course of P/P therapy Jun Yamagami, MD, PhD, Keio University, Tokyo, Japan
  • 4:00pm – 4:15pm – Assessing the “Quality” of Quality of Life Surveys in Autoimmune Blistering Disease – Victoria Werth, MD, University of Pennsylvania, Philadelphia, USA
  • 4:15pm – 4:45pm – Panel discussion of P/P enrollment and clinical trial instruments

Session 3: Patient reported outcomes 

Moderators – Meng Pan (Shanghai, China), Animesh Sinha (Buffalo, USA)
This session will summarize the Natural History Study being conducted by the International Pemphigus and Pemphigoid Foundation (IPPF). The second part of the session will feature a panel discussion to allow patients who have participated in recent trials, industry and investigators to share their experiences in clinical trials.

  • 5:00pm – 5:15pmNatural history study in P/P Marc Yale, IPPF, Sacramento, USA
  • 5:15pm – 6:00pmPanel discussion on patient and pharma experience in clinical trialsDiana Chen, MD, MBA, Senior Medical Director, Genentech; Steve Gourlay, MBBS, FRACP, PhD, Chief Medical Officer, Principia Biopharma; Jeff Weisgerber, North Carolina, Pemphigus Vulgaris Patient; Odette Miller, New Jersey, Pemphigus Vulgaris Patient

Session 4: Cooperative Networks for Rare Disease Research 

  • 6:00pm – 6:30pmCocktails and Networking
  • 6:30pm – 7:30pmDinner
  • 7:30pm – 8:30pmKeynote speaker – David Fajgenbaum, MD, MBA, Co-founder – Castleman’s Disease Collaborative Network, Assistant Professor – University of Pennsylvania, Philadelphia, USA
  • 8:30pm – 10:00pm – Reception and Poster Session

Wednesday May 16, 2018

  • 8:00am – 9:30am – Breakfast

Session 5: Clinical trials of novel cellular therapies for pemphigus 

Moderators – Detlef Zillikens (Lübeck, Germany), Donna Culton (Raleigh, USA)
This session will discuss novel approaches to cellular therapy, focusing on pemphigus as a model autoantibody-mediated disease. 

  • 9:30am – 9:45amImmune tolerance in pemphigus – Rüdiger Eming, MD, Marburg University, Marburg, Germany
  • 9:45am – 10:00amGene-engineered cell therapies in pemphigus – Aimee Payne, MD, PhD, University of Pennsylvania, Philadelphia, USA
  • 10:00am – 10:15amRegulatory T cells for treatment of autoimmune diseases – Haley Naik, MD, University of California, San Francisco, USA
  • 10:15am – 10:30am – Panel discussion of cellular therapies for pemphigus

Session 6: Emerging therapies in clinical development in P/P 

Moderators – Peter Marinkovich (Stanford, USA), Soo-Chan Kim (Seoul, South Korea)
This session will cover clinical trials that will open in 2017-2018 for P/P. 

  • 10:45am – 11:00amUnmet needs in pemphigoid diseases: an international survey amongst patients, clinicians and researchers – Marcel Jonkman, MD, University Medical Center Groningen, Netherlands
  • 11:00am – 11:15amDimethyl fumarate in bullous pemphigoid – Ralf Ludwig, MD, University of Lübeck, Lübeck, Germany
  • 11:15am – 11:30am – The C5a-LTB4 in bullous pemphigoid diseases – opening the door for granulocytes into the skin – Christian Sadik, MD, University of Lübeck, Lübeck, Germany
  • 11:30am – 11:45am – Panel discussion of emerging therapies in P/P
  • 12:00pm – 1:00pm – Lunch

Session 7: Pre-IID spotlight with lunch 

Moderators – Aimee Payne (Philadelphia, USA), Victoria Werth (Philadelphia, USA)
Brief oral presentations selected from submitted abstracts.

  • 1:00pm – 1:06pm  – Ron Feldman, MD, PhD, Atlanta, USA: Defining treatment efficacy and potential biomarkers following Rituximab therapy in patients with bullous pemphigoid
  • 1:08pm – 1:14pm – Aniek Lamberts, MD, Groningen, Netherlands: Effectiveness and safety of Rituximab in recalcitrant pemphigoid diseases
  • 1:16pm  1:22pm  – Roberta Lotti, MD, Modena, Italy: PC111: a monoclonal anti-Fas Ligand antibody for the treatment of pemphigus
  • 1:24pm – 1:30pm – Gabriel Cipolla, PhD, Curitiba, Brazil: miR-223-3p is upregulated by igG of pemphigus and activates the p38 MAPK pathway through direct inhibition of DUSP10
  • 1:32pm – 1:38pm – Catherine Prost, MD, Bobigny, France: Efficacy of Omalizumab therapy in bullous pemphigoid and mucous membrane pemphigoid
  • 1:40pm – 1:46pm – Farzan Solimani, MD, Marburg, Germany: T cell subsets shape the clinical phenotype in autoimmunity against desmosomal and hemidesmosomal adhesion molecules

1:54pm – 2:10pm – Come see my poster; Pre-IID Spotlight

  • Kaisa Tasanen, MD (Oulu, Finland): “Vildagliptin significantly increases the risk of bullous pemphigoid: A Finnish nationwide registry study”
  • Joost Meijer, MD (Groninger, Netherlands): “Prevalence of pruritus and pemphigoid in nursing home residents (SSENIOR): a cross-sectional study of an unmet need”
  • Carolyn Kushner, BS (Philadelphia, USA): “Factors predictive of complete remission off therapy after a single cycle of rituximab for pemphigus”
  • Jennifer Hundt, MD (Lübeck, Germany): “The role of circadian clocks in a murine model of antibody-induced skin inflammation”
  • Jane Setterfield, MD (London, England): “An Oral Disease Severity Score validated for use in Mucous Membrane Pemphigoid”
  • Stephanie Goletz, MD (Lübeck, Germany): “Sensitive and specific assays for the serological diagnosis of anti-laminin 332 mucous membrane pemphigoid”
  • Marian Dmochowski, MD (Poznan, Poland): “Comparative analysis of occurrence of IgG antibodies to BP180/BP230 and so-called IgG anti-neuronal antibodies in bullous pemphigoid coexistent with neurodegenerative diseases”
  • Animesh Sinha, MD, PhD (Buffalo, USA): “Development of a Digital Solution to Facilitate Patient Physician Interactions in Pemphigus”

2:15pm – 2:30pm – Meeting Wrap up: Aimee S. Payne, MD, PhD

Poster presentations:

  • Sharon Baum, MD (Tel Aviv, Israel):  The Progressive Response of Repeated Rituximab Doses in the Treatment of Pemphigus Vulgaris
  • Carolyn Kushner, BS (Philadelphia, USA): Assessing the “Quality” of Quality of Life Surveys in Autoimmune Blistering Disease
  • Johann Bauer, MD (Salzburg, Austria): Cross-tumoral evolution of bullous pemphigoid after PD-1 inhibition
  • Marcel Jonkman, MD, PhD (Groningen, Netherlands): Diagnostic strategy for bullous and nonbullous pemphigoid: a paired multivariable diagnostic accuracy study
  • Marian Dmochowski, MD (Poznan, Poland): Dew drops on spider web appearance is a newly named, diagnostically valuable, pattern of Th2-dependent IgG4 deposition in pemphigus diseases at an active-stage with direct immunofluorescence techniques: Implications for treatment
  • Valeria Aoki, MD (São Paulo, Brazil): Epidermolysis Bullosa Acquisita: a Prospective Multidisciplinary Study
  • Tony Fiorino, MD (Englewood Cliffs, USA): A Pilot Phase 2a Study of the Safety and Efficacy of Bertilimumab, an Anti-Eotaxin-1 Antibody, in Bullous Pemphigoid
Travel & Hotel Information


Orlando International Airport, Orlando, Florida (MCO)

The Rosen Shingle Creek is approximately 25 minutes from Orlando International Airport.

Rosen Shingle Creek is conveniently located on Universal Boulevard just off of the Beachline Expressway (SR 528, Exit #2) and a half mile east of the Orange County Convention Center. This ideal location is also minutes away from Orlando’s world-famous attractions like Universal Orlando®, Aquatica, Seaworld Orlando® and others.

For group transportation, call (407) 839-1570

For shuttle and towncar transportation to and from Orlando International Airport:

For Rental Cars:

Valet Parking – $26



Rosen Shingle Creek, which opened September 9, 2006, is one of the largest full-service convention hotels in Central Florida. The 255-acre hotel offers 1,501 guest rooms and suites, and 524,000 square feet of dedicated, flexible meeting/event space that includes one of the nation’s largest column-free ballrooms at 95,000 sq. ft. Awarded the AAA Four Diamond designation annually since 2007, the hotel offers an array of amenities such as:

  • BAGS — Transportation Security Administration-approved remote skycap service allows guests to receive their airline boarding passes and check their luggage directly from the hotel
  • Universal Orlando Hotel Partner, where guests enjoy complimentary scheduled daily transportation from the hotel to and from Universal Orlando® Resort exciting theme parks and to SeaWorld® Orlando and Aquatica®
  • Regular transportation to Orlando International Airport
  • Full service on-site concierge desk
  • On-site RICOH Business Center and gift shop
  • Self and valet parking (self-parking: $18.00, valet parking: $26.00 plus tax, subject to change)
  • Electric car charging station available
  • Complimentary valet parking for disabled guests
  • Attraction ticket sales and scheduled transportation arrangements
  • Private tour guides and translators
  • On-site babysitting service (reservations required)
  • Upscale guest laundry room, open 24 hours and valet services
  • Complimentary Wi-Fi in all guest rooms and public areas
  • For guests with disabilities, the hotel offers complimentary valet parking, ramps, elevators, automatic lobby doors, Braille signs on each floor and a zero entry pool. The hotel offers 75 ADA accessible guest rooms each with rails around the toilet and in the tub, some with roll in showers. Rental scooters are located outside by the valet parking booth.

Thank You to Our Sponsors